Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMY W ZHOU

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1831331990
CMS profile
2353623
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$344.55

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $313.22 5
Education $31.33 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
CTI BioPharma Corp. $313.22 5
Blueprint Medicines Corporation $31.33 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMY W ZHOU

NPI 1831331990 · CMS profile ID 2353623

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831331990?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMY W ZHOU, NPI 1831331990, CMS profile ID 2353623. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831331990?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AMY W ZHOU, NPI 1831331990, CMS profile ID 2353623. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831331990?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AMY W ZHOU, NPI 1831331990, CMS profile ID 2353623, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1831331990?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $344.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CTI BioPharma Corp. $122.7810/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039687809 CMS
Blueprint Medicines Corporation $31.3307/25/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051258117 CMS
CTI BioPharma Corp. $7.4006/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039687805 CMS
CTI BioPharma Corp. $6.8504/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039687801 CMS
CTI BioPharma Corp. $7.5303/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039687797 CMS
CTI BioPharma Corp. $168.6601/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039687793 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,509.56 5
PY2022 $4,742.49 4
PY2023 $344.55 6
PY2024 $2,862.59 3
PY2025 $2,635.66 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $64,938.42 238
PY2024 Principal investigator $1,200.00 1
PY2022 Principal investigator $53,556.80 1
PY2020 Principal investigator $13,300.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

238 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Sumitomo Pharma America, Inc. $17,800.48 12/17/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176657213
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656161
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656165
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656168
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656172
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656177
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656181
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656185
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656189
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656191
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656195
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656200
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656205
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656209
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656213
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656217
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656221
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656224
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656229
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656233
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656237
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656241
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656245
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656249
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656253
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656258
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656262
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656266
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656270
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656273
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656277
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656282
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656286
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656289
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656293
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656298
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656302
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656306
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656310
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656313
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656319
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656323
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656327
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656332
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656336
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656339
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656343
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656347
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 12/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176656351
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 10/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176651481
Principal investigator 1 Sumitomo Pharma America, Inc. $1,622.00 10/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176651484
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 10/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176650535
Principal investigator 1 Sumitomo Pharma America, Inc. $544.38 10/06/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176650539
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648334
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648337
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648340
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648344
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648346
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648350
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648353
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648357
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648360
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648363
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648367
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648371
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648375
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648379
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648383
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648388
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648393
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648397
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648400
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648404
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648411
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648415
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648419
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648422
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648427
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648432
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648437
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648441
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648445
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648449
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648452
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648456
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648461
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648464
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648468
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648473
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648477
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648481
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648485
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648491
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648497
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648501
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648506
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648509
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648513
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648518
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648521
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648527
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648532
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648536
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648540
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648544
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648548
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648552
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648558
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648561
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648565
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648568
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648572
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648576
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648580
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648584
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648587
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648592
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648596
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648600
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648604
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648607
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648611
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648615
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648619
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648623
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648627
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648630
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648634
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648637
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648641
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648646
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648651
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648655
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648659
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648662
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648666
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648670
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648674
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648678
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648682
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648686
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648690
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648693
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648697
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648700
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648705
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648708
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648712
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648716
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648720
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648724
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648728
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648731
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648735
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648740
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648744
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648749
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648752
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648756
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648761
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648764
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648768
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648772
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648776
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648780
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648784
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648788
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648792
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648794
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648798
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648802
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648805
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648809
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648813
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648816
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648821
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648825
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648829
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648833
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648838
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648843
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648847
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648850
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648855
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648858
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648861
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648865
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648869
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648873
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648876
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176648880
Principal investigator 1 Sumitomo Pharma America, Inc. $13,491.00 07/24/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176641275
Principal investigator 1 Sumitomo Pharma America, Inc. $25,951.00 02/20/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176628348
Principal investigator 1 Sumitomo Pharma America, Inc. $280.00 02/11/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176627389
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623045
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623048
Principal investigator 1 Sumitomo Pharma America, Inc. $8.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623052
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623056
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623060
Principal investigator 1 Sumitomo Pharma America, Inc. $16.20 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623064
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623068
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623071
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623074
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623078
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623082
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623086
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623089
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623093
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623098
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623101
Principal investigator 1 Sumitomo Pharma America, Inc. $43.70 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623105
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623112
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623115
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623120
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623126
Principal investigator 1 Sumitomo Pharma America, Inc. $0.25 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623130
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623134
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623137
Principal investigator 1 Sumitomo Pharma America, Inc. $0.50 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623142
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623146
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623149
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623154
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623158
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623161
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623165
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623168
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623173
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623177
Principal investigator 1 Sumitomo Pharma America, Inc. $14.10 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623181
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623184
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623189
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623192
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623196
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623199
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623204
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623208
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623212
Principal investigator 1 Sumitomo Pharma America, Inc. $24.00 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY AT ST LOUIS
A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS No dispute reported 06/30/2026 1176623215